Beryl Drugs Ltd Valuation Shifts to Very Attractive Amid Mixed Market Returns

Valuation Metrics Show Marked Improvement

As of 10 June 2026, Beryl Drugs trades at ₹24.25, marginally down 0.33% from the previous close of ₹24.33. The stock’s 52-week range spans from ₹15.92 to ₹30.00, indicating a recovery from its lows but still below its peak levels. The company’s P/E ratio currently stands at 29.28, a figure that, while elevated compared to broader market averages, is considered very attractive within its peer group. This is a marked improvement from previous valuation grades, which had been less favourable.

Complementing the P/E, the price-to-book value ratio is at a modest 1.24, signalling that the stock is trading close to its book value and suggesting limited downside risk from a valuation standpoint. Other enterprise value multiples such as EV/EBITDA at 6.00 and EV/EBIT at 14.47 further reinforce the stock’s relative affordability, especially when contrasted with peers in the Pharmaceuticals & Biotechnology sector.

Comparative Analysis with Industry Peers

When benchmarked against key competitors, Beryl Drugs’ valuation stands out for its relative attractiveness. For instance, Bliss GVS Pharma and Kwality Pharma are both classified as very expensive, with P/E ratios of 34.19 and 35.71 respectively, and EV/EBITDA multiples exceeding 20. Similarly, Hester Biosciences and Shukra Pharma trade at elevated multiples, with P/E ratios above 30 and EV/EBITDA multiples near or above 20. In contrast, Beryl Drugs’ EV/EBITDA of 6.00 is significantly lower, underscoring its valuation appeal.

Venus Remedies and Syncom Formulations, rated as fair in valuation, have P/E ratios of 20.83 and 17.90 respectively, which are lower than Beryl Drugs but accompanied by higher EV/EBITDA multiples. This suggests that while Beryl Drugs commands a premium on earnings, its overall enterprise valuation remains conservative.

Financial Performance and Returns Contextualise Valuation

Beryl Drugs’ return metrics over various time horizons provide further context to its valuation. The stock has delivered a robust 24.68% return over the past year, outperforming the Sensex which declined by 10.34% in the same period. Over three and five years, the stock’s returns have been even more impressive at 60.17% and 181.32% respectively, dwarfing the Sensex’s 18.03% and 42.31% gains. However, the 10-year return is negative at -32.92%, contrasting with the Sensex’s strong 176.19% growth, indicating a volatile long-term performance.

These returns highlight the stock’s capacity for strong medium-term gains, which may justify its current valuation premium relative to some peers. However, the negative decade-long performance suggests caution and the need for investors to consider the company’s recent turnaround and future growth prospects carefully.

Profitability and Efficiency Metrics

Profitability ratios such as return on capital employed (ROCE) and return on equity (ROE) provide insight into operational efficiency. Beryl Drugs reports a ROCE of 7.63% and an ROE of 4.25%, figures that are modest but indicate positive returns on invested capital. These metrics, while not outstanding, support the valuation upgrade to very attractive, especially when combined with the company’s improving earnings profile and valuation multiples.

The PEG ratio is reported as zero, which may reflect either a lack of earnings growth projection or data unavailability. This absence of growth premium suggests that the current valuation is primarily driven by earnings and book value metrics rather than anticipated rapid expansion.

Market Capitalisation and Analyst Ratings

Beryl Drugs remains classified as a micro-cap stock, which typically entails higher volatility and risk but also potential for outsized returns. The company’s Mojo Score is 37.0, with a recent upgrade in Mojo Grade from Strong Sell to Sell as of 6 May 2026. This shift indicates a cautious improvement in sentiment but still reflects a bearish stance from the rating agency. Investors should weigh this rating alongside valuation improvements and financial metrics to form a balanced view.

Valuation Shifts Reflect Changing Market Perceptions

The upgrade in valuation grade from attractive to very attractive signals a shift in market perception towards Beryl Drugs. This change is underpinned by the company’s improved price multiples relative to peers and its historical valuation band. The P/E ratio of 29.28, while higher than some sector averages, is justified by the company’s recent performance and relative affordability compared to very expensive peers trading above 30 times earnings.

Similarly, the price-to-book ratio of 1.24 suggests that the stock is not overvalued on a net asset basis, providing a margin of safety for investors. Enterprise value multiples such as EV/EBITDA at 6.00 and EV/Capital Employed at 1.20 further reinforce the stock’s valuation appeal, indicating that the market is pricing the company conservatively relative to its earnings and capital base.

Risks and Considerations

Despite the positive valuation shift, investors should remain mindful of the company’s micro-cap status, which can entail liquidity constraints and higher volatility. The modest profitability ratios and the zero PEG ratio highlight that growth prospects may be limited or uncertain at present. Additionally, the downgrade from Strong Sell to Sell Mojo Grade, while an improvement, still suggests caution.

Comparisons with peers such as Ind-Swift Laboratories, rated as risky with a P/E of 28.53 but a much higher EV/EBITDA of 33.57, illustrate the diverse risk-return profiles within the sector. Investors should consider Beryl Drugs’ valuation in the context of its financial health, sector dynamics, and broader market conditions.

Outlook and Investor Implications

For investors seeking exposure to the Pharmaceuticals & Biotechnology sector through a micro-cap stock, Beryl Drugs presents an intriguing proposition given its improved valuation metrics and recent performance. The stock’s strong medium-term returns relative to the Sensex and its very attractive valuation grade suggest potential for further upside, particularly if profitability and growth metrics improve.

However, the company’s modest ROCE and ROE, alongside a cautious Mojo Grade, imply that investors should adopt a measured approach, balancing the valuation appeal against inherent risks. Monitoring upcoming earnings releases and sector developments will be crucial to reassessing the stock’s investment case.

Conclusion

Beryl Drugs Ltd’s transition to a very attractive valuation grade marks a significant milestone in its market journey. The stock’s improved P/E and P/BV ratios relative to peers and historical levels enhance its price attractiveness, supported by solid medium-term returns and reasonable profitability. While risks remain, particularly given its micro-cap status and modest growth outlook, the valuation shift offers a compelling reason for investors to re-examine the stock within their portfolios.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →